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ABSTRACT
Objective: To evaluate different weight loss (WL) cut-off points as prognostic markers 
of 3-month survival after diagnosis of stage IV non-small cell lung cancer (NSCLC). 
Methods: This was a prospective study involving 104 patients with metastatic (stage 
IV) NSCLC who were admitted to a cancer treatment center in southern Brazil between 
January of 2014 and November of 2016. We evaluated total WL and WL per month, as 
well as WL and WL per month in the 6 months preceding the diagnosis. The patients 
were followed for 3 months after diagnosis. A Cox proportional hazards regression model 
and Kaplan-Meier curves were used in order to evaluate 3-month survival. Results: The 
median WL in the 6 months preceding the diagnosis was 6% (interquartile range, 0.0-
12.9%). Patients with WL ≥ 5% had a median survival of 78 days, compared with 85 
days for those with WL < 5% (p = 0.047). Survival at 3 months was 72% for the patients 
with WL ≥ 5% (p = 0.047), 61% for those with WL ≥ 10% (p < 0.001), and 45% for 
those with WL ≥ 15% (p < 0.001). In the multivariate analysis, the hazard ratio for risk 
of death was 4.51 (95% CI: 1.32-15.39) for the patients with WL ≥ 5%, 6.34 (95% CI: 
2.31-17.40) for those with WL ≥ 10%, and 14.17 (95% CI: 5.06-39.65) for those with 
WL ≥ 15%. Conclusions: WL in the 6 months preceding the diagnosis of NSCLC is a 
relevant prognostic factor and appears to be directly proportional to the rate of survival 
at 3 months. 
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INTRODUCTION
Weight loss (WL) is a common complaint of patients with lung cancer and a common 
reason for patient referral to a specialist.(1-3) Cancer cachexia, resulting from an 
imbalance between energy intake and consumption, is associated with a combination 
of poor caloric intake and increased resting energy expenditure, probably due to a 
cytokine-induced systemic inﬂ ammatory response.(4-7) Some studies have demonstrated 
that this increase in resting energy expenditure can also vary depending on the 
type of tumor.(8,9) Other factors that contribute to cancer cachexia include nausea, 
vomiting, constipation, diarrhea, pain, altered taste perception, and depression.(1)
Despite its potential beneﬁ t for the clinical evaluation of patients with non-small 
cell lung cancer (NSCLC), the deﬁ nition of cachexia varies signiﬁ cantly across studies 
and many WL cut-off points have been proposed in the attempt to classify the 
syndrome in an objective manner.(10-14) A recent consensus suggested that WL be 
deﬁ ned as any decrease greater than 5% in relation to the usual weight or greater 
than 2% in individuals with a body mass index < 20 kg/m2.(13) However, setting up a 
single cut-off point to classify cachexia can underestimate its real prognostic value. 
Different levels of cachexia severity can have various effects on the prognosis of 
cancer and could serve as a valuable clinical indicator. 
The objective of this study was to evaluate 3-month survival in a population of 
patients with stage IV NSCLC. We also tested the prognostic value of different WL 
cut-off points.
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METHODS
Study population
This prospective cohort study was conducted at 
Santa Rita Hospital, an oncology referral center and 
part of the Santa Casa de Misericórdia de Porto Alegre 
Hospital Complex, in the city of Porto Alegre, located 
in southern Brazil. We included consecutive patients 
newly diagnosed with metastatic (stage IV) NSCLC and 
admitted to Santa Rita Hospital between January of 
2014 and November of 2016. Patients were treated at 
the discretion of the attending physician. All patients 
received a nutritional consultation at admission, regularly 
received high-calorie meals, and were instructed to 
rest before meals. However, they did not receive any 
type of nutritional supplementation as part of the 
palliative care or during chemotherapy. The follow-up 
period was ≤ 3 months after the diagnosis of cancer, 
as conﬁ rmed by reviews of medical records, hospital 
records, and phone calls. All diagnoses required clinical, 
radiological, and histological conﬁ rmation. Patients who 
had previously undergone antineoplastic treatment were 
excluded, as were those who were under 18 years of 
age. Survival and mortality rates were calculated from 
the time of the histological diagnosis until death or until 
the end of the third month of follow-up. Patient charts 
were reviewed, and tumor-node-metastasis variables 
were upgraded in accordance with the revised stage 
groupings established by the International Association 
for the Study of Lung Cancer.(15) Performance status 
was assessed with the Eastern Cooperative Oncology 
Group scale.(16) The study was approved by the local 
institutional review board. All participating patients 
gave written informed consent.
WL classiﬁ cation
Each patient was prospectively evaluated following 
the standards established in previous reports.(17) 
Deﬁ nitions of WL-related variables were also based on 
those established in other studies(10): total WL—the 
difference between weight at the time of diagnosis 
and usual weight; WL per month—total WL divided by 
the number of months of WL; and WL per month in 6 
months—total difference between weight at the time 
of diagnosis and weight in the preceding 6 months. 
Patients were also subjectively evaluated in terms 
of their self-awareness of WL at the time of NSCLC 
diagnosis in relation to their usual weight. Different 
WL cut-off points (5%, 10%, and 15%) were tested in 
order to classify cachexia and to correlate the different 
de grees of cachexia with the survival rates.
Statistical analysis
Continuous variables are expressed as medians and 
interquartile range (IQR). Univariate analyses of survival 
were based on the Kaplan-Meier method.(18) Survival 
was calculated by Cox proportional hazards regression 
model in a multivariate analysis.(19) The Wald test was 
used in order to calculate signiﬁ cance for each factor. 
All parameters associated with mortality (p < 0.1) in 
the univariate analysis were included in a multivariate 
model, in which values of p < 0.05 were considered 
statistically signiﬁ cant. All tests were two-tailed, with 
the level of signiﬁ cance set at 0.05. All results were 
analyzed with the SPSS Statistics software package, 
version 20.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Patient characteristics are summarized in Table 1. 
The median age was 63 years (IQR, 52.5-69.0 years). 
Of a total of 104 patients evaluated, 63 (60.6%) were 
male. The most prevalent histological type of NSCLC 
was adenocarcinoma, which was seen in 57 (54.7%) 
of the patients, followed by squamous cell carcinoma, 
seen in 36 (34.6%), and mixed/undeﬁ ned, seen in 11 
(10.6%). The median Eastern Cooperative Oncology 
Group performance status was 2 (IQR, 1-3). Most 
(60.6%) of the patients underwent chemotherapy after 
diagnosis. Of the 104 patients, 44 (42.3%) underwent 
radiation therapy and 10 (9.6%) received supportive 
care exclusively. The 3-month mortality rate was 20.1% 
(95% CI: 12.9-29.1), 21 patients dying within the 
ﬁ rst 3 months after being diagnosed with cancer. The 
median WL in 6 months was 6% (IQR, 0.0-12.9%).
Patient outcomes, stratiﬁ ed by WL cut-off points, 
are summarized in Table 2. All cut-off points for WL in 
6 months were statistically associated with a poorer 
prognosis as assessed by mean days of survival in 3 
months. Patients with WL ≥ 5% had a mean survival 
of 78 days, compared with 85 days for those with WL 
< 5% (p = 0.047). When the WL cut-off points of ≥ 
10% and ≥ 15% were applied, the mean survival 
decreased to 73 days and 66 days, respectively (p < 
0.001 for both). However, there was no statistically 
signiﬁ cant difference between the patients who were 
aware of their WL and those who were not in terms 
of the 3-month survival rate (p = 0.081). 
Kaplan-Meier survival curves for the ﬁ rst 3 months 
after diagnosis are shown in Figure 1. We observed a 
direct linear trend between the proportional WL and 
mortality. Event-free survival at 3 months was 88% 
for the patients with WL < 5%, compared with 72% 
for those with WL ≥ 5% (p = 0.04 7), 61% for those 
with WL ≥ 10% (p < 0.001), and 45% for those with 
WL ≥ 15% (p < 0.001).
The outcomes of the Cox proportional hazards 
regression model are summarized in Table 3. The 
univariate and multivariate (adjusted) analyses both 
demonstrated that the risk of death during the 3-month 
follow-up period was higher when the higher WL cut-off 
points were applied. The adjusted multivariate analysis 
showed that the risk of death increases exponentially 
as the cut-off points of WL increase, the hazard ratios 
for the 5%, 10%, and 15% cut-off points being 4.51 
(95% CI: 1.32-15.39), 6.34 (95% CI: 2.31-17.40), 
and 14.17 (95% CI: 5.06-39.65), respectively.
DISCUSSION
In the present study, our aim was to determine the 
value of WL as a prognostic factor in patients with 
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NSCLC, as well as whether that association differs among 
four WL cut-off points. We have shown that greater WL 
translates to shorter overall survival for patients with 
NSCLC. We found that, among patients with advanced 
NSCLC, the 3-month mortality rate was almost two 
times higher for those with WL ≥ 15% than for those 
with WL < 5%. Our results suggest that pre-treatment 
WL is an important clinical parameter with relevant 
prognostic value in patients with advanced NSCLC. 
Our findings are consistent with those of 
previous studies that evaluated survival and WL in 
populations of lung cancer patients that were more 
heterogeneous, including patients in different stages 
of the disease. (1-3,10-12,20-22) The prognostic signiﬁ cance 
of WL in stage IV NSCLC could be attributed to the 
potential link to cachexia. Deﬁ ned as a multifactorial 
syndrome of progressive loss of skeletal muscle mass 
that cannot be completely reversed, cachexia has a 
heterogeneous clinical presentation that varies according 
to tumor type, site, and stage.(13,21) Lung cancer is often 
accompanied by malnutrition, sarcopenia, and cachexia. 
Following the cancer-speciﬁ c cachexia classiﬁ cations, 
van der Meij et al.(23) demonstrated that, at the time 
of diagnosis, approximately 18% and 23% of stage 
III NSCLC patients had cachexia or were in a state of 
pre-cachexia, respectively. However, the exact basis 
of these prognostic differences remains unknown. 
Several hypotheses have been proposed to explain 
the association between cachexia and poorer 
prognosis. Some authors have suggested that the 
survival advantage associated with obesity is due to 
the relatively large energy stores.(21-23) Conversely, 
Table 1. Baseline anthropometric and clinical characteristics of the study sample.
Characteristic N = 104
Male gender, n (%) 63 (60.6)
Age (years), median (IQR) 63 (52.5 to 69.0)
Body weight at diagnosis (kg), median (IQR) 63 (53.0 to 70.7)
Patient awareness of WL, n (%) 67 (64.4)
Smoking status, n (%)
Non-smoker 18 (17.3)
Former smoker 51 (49.0)
Current smoker 35 (33.7)
Total WL, median (IQR) −6.0% (−12.9% to 0%)
WL per month, median (IQR) −1.0% (−2.1% to 0%)
WL in 6 months, median (IQR) −6.0% (−12.4% to 0%)
WL in 6 months ≥ 5%, n (%) 59 (56.7)
WL in 6 months ≥ 10%, n (%) 36 (34.6)
WL in 6 months ≥ 15%, n (%) 22 (21.2)
ECOG PS, median (IQR) 2 (1 to 3)
Tumor cell type, n (%)
Adenocarcinoma 57 (54.8)
Squamous cell carcinoma 36 (34.6)
Mixed or undeﬁ ned histology 11 (10.6)
Main treatment, n (%)
Chemotherapy 63 (60.6)
Supportive care only 10 (9.6)
Radiation therapy 44 (42.3)
IQR: interquartile range; WL: weight loss; and ECOG-PS: Eastern Cooperative Oncology Group performance status.
Table 2. Kaplan-Meier survival analysis, by weight loss-related variable.
Variable Mean survival χ2 p*
Days (95% CI)
WL, self-awareness
Yes 85 (80-89) 3.05 0.080
No 78 (73-84)
Proportional WL in 6 months
< 5% 85 (80-89) 3.94 0.047
≥ 5% 78 (72-84)
< 10% 85 (81-89) 11.58 < 0.001
≥ 10% 73 (64-82)
< 15% 85 (81-88) 23.78 < 0.001
≥ 15% 66 (53-78)
WL: weight loss. *Log-rank test.
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when the stores are depleted, the energy balance is 
negative.(21-23) Cachexia and a loss of skeletal muscle 
mass are associated with poor prognosis in patients with 
advanced NSCLC who are receiving chemotherapy.(10,24) 
Another hypothesis is that individuals with sarcopenia 
are susceptible to infections during hospitalization and 
residence in nursing homes, where such infections and 
premature termination of treatment are both possible 
contributors to shortened survival.(25) Accordingly, 
the well-recognized poor prognosis in advanced lung 
cancer masks some heterogeneity that could be 
partially explained by WL stratiﬁ cation and other, as 
yet unconﬁ rmed, biological factors. 
Cachexia is a multifactorial syndrome with a complex 
pathogenesis. Therefore, multimodal interventions 
should be used in order to prevent WL among patients 
with cachexia.(26) Frequent high-calorie meals and 
rest before meals are recommended. Currently, there 
is little evidence that nutritional supplementation is 
efﬁ cacious. (27) Physical activity has an anti-inﬂ ammatory 
effect and is effective in reducing muscle catabolism, 
increasing protein synthesis, and reversing protein 
degradation. (28) Pharmacological treatment can also 
be used to prevent cachexia. Corticosteroids and 
progesterone analogs have been shown to increase 
appetite, thus resulting in modest weight gain. However, 
such drugs do not improve survival or quality of life.(29)
Our study has some limitations, not the least of which 
is the small sample size. In addition, there are many 
confounding variables that could inﬂ uence the analysis 
of 3-month survival of patients with advanced NSCLC. 
One such variable is the main treatment adopted, which, 
in our sample. was quite heterogeneous, therefore 
potentially affecting the prognosis. However, we believe 
that using a Cox proportional hazards regression model 
was an effective strategy to reduce the inﬂ uence of those 
confounders, and the associations detected retained 
their signiﬁ cance even after the multivariate analyses. 
Studies including larger patient samples are needed 
in order to corroborate our ﬁ ndings. Further studies 
should also include biomarkers linked to aggressive 
behavior of lung cancer, such as circulating tumor cells 
and circulating cell-free nucleic acids, which could 
also affect survival rates, and patients who have such 
biomarkers might show different rates of WL.(30)
Although increased efforts have been directed toward 
the identiﬁ cation of biological markers as prognostic 
indicators of lung cancer, there are some important 
clinical indices that should be also considered more 
thoroughly. In conclusion, our results indicate that 
proportional WL is an important prognostic factor 
for 3-month survival after diagnosis in patients with 
stage IV NSCLC.
Table 3. Crude and adjusted hazard ratios for weight-loss related prognostic factors.
Variable Crude HR (95% CI) p Adjusted HR* (95% CI) p
WL, self-awareness 2.54 (0.86-7.49) 0.089 3.59 (1.03-12.48) 0.044
WL in 6 months ≥ 5% 2.65 (0.97-7.21) 0.055 4.51 (1.32-15.39) 0.016
WL in 6 months ≥ 10% 4.45 (1.80-10.99) 0.001 6.34 (2.31-17.40) < 0.001
WL in 6 months ≥ 15% 6.53 (2.76-15.44) < 0.001 14.17 (5.06-39.65) < 0.001
HR: hazard ratio; and WL: weight loss. *Cox proportional hazards regression model analysis, adjusted for gender, 
age, Eastern Cooperative Oncology Group performance status, and tumor cell type.
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